218 related articles for article (PubMed ID: 14563000)
1. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
[TBL] [Abstract][Full Text] [Related]
2. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
4. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
5. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
6. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
[TBL] [Abstract][Full Text] [Related]
7. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
10. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Evans G; Bryant HU; Magee D; Sato M; Turner RT
Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
[TBL] [Abstract][Full Text] [Related]
11. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
[TBL] [Abstract][Full Text] [Related]
12. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
13. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
15. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
[TBL] [Abstract][Full Text] [Related]
16. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice.
Zeitlin L; Segev E; Fried A; Wientroub S
J Cell Biochem; 2003 Oct; 90(2):347-60. PubMed ID: 14505351
[TBL] [Abstract][Full Text] [Related]
18. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Palkowitz A; Jee WS; Turner CH; Sato M
J Bone Miner Res; 2002 Dec; 17(12):2256-64. PubMed ID: 12469920
[TBL] [Abstract][Full Text] [Related]
19. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
Stygar D; Muravitskaya N; Eriksson B; Eriksson H; Sahlin L
Reprod Biol Endocrinol; 2003 May; 1():40. PubMed ID: 12777179
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
